

PARTNER DISCUSSIONS ENCOURAGING

Melbourne, Australia 27th April 2017: Respiri Limited is viewed as an innovative, high potential MedTech company that partners with patients and healthcare providers to transform asthma care. The company's clear, overarching objective is to deliver partnership agreements to gain access to global markets.

Partner discussions have been ramped up following the successful research trials at the University of Chicago in November 2016 and the receipt of Class IIa CE Mark approval for the AirSonea home monitoring device in March 2017.

Our focus in recent weeks has been on Asia, including exciting opportunities in China where air pollution is driving the increase in asthma, COPD (Chronic Obstructive Pulmonary Disease) and other respiratory diseases.

Respiri has clear objectives that underpin all partnership discussions:

- Technical collaboration and financial arrangements with one or more partners to design and produce the hardware for the next generation AirSonea® wheeze monitor.
- Sales and distribution agreements that provide significant distribution and sales capacity for our device hardware and leading edge technology platform.

Respiri expects to receive written commercial-in-confidence proposals by the end of May 2017 from at least two potential partners in China.

Leon L'Huillier
Executive Chairman
Ph: 1800 476 632